Mirella Daja
Novo Nordisk Pharmaceuticals Pty Ltd, Australia, NSW, Australia
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
Patients are more likely to reach A1c target at any given time during 26 weeks' treatment with liraglutide compared with both sitagliptin and exenatide (#372)
2:00 PM
Mirella Daja
ADS Clinical Poster Discussions
Once daily liraglutide (1.2mg) vs twice daily exenatide (10ug) in the treatment of type 2 diabetes patients: a meta-analysis. (#374)
2:00 PM
Mirella Daja
ADS Clinical Poster Discussions